Moderna Stock Jumps 16% on Flu Vaccine Breakthrough and Analyst Optimism

Moderna shares surged over 16% following the publication of Phase 3 trial results for its mRNA flu vaccine, mRNA-1010, in the New England Journal of Medicine. The data demonstrated superiority over standard flu vaccines in adults aged 50 and older, fueling investor confidence.

Analyst upgrades compounded the rally, with Evercore ISI, Goldman Sachs, and Piper Sandler raising price targets or initiating buy ratings. The FDA's August 5 PDUFA date for mRNA-1010 adds near-term catalysts, while filings progress in Europe, Canada, and Australia.

Peripheral attention briefly turned to Moderna's early-stage hantavirus program after cruise-linked cases emerged, though analysts dismissed material revenue potential. The stock's momentum contrasts with Pfizer and BioNTech's struggles to enroll participants in a competing COVID vaccine trial.